News archive

December 19, 2024
Human-first drug discovery: how start-ups can stay ahead of the game
November 27, 2024
More good drugs than ever: a boon for society but a challenge for company coffers
October 21, 2024
Zapping weeds: RootWave’s herbicide-free weed control solution
September 25, 2024
The rise and recalibration of sustainable agri-food investments: lessons for us all
August 21, 2024
Mutually beneficial success: the importance of the founder-VC partnership
April 24, 2024
Will the looming pharma patent cliff start driving a super cycle of biotech deals?
April 24, 2024
V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors
March 26, 2024
Fraud in scientific institutes: a crack in the fabric of science
February 21, 2024
Bridging the immunity gap: improving animal welfare without antibiotics
January 19, 2024
How the Chair of the Board can empower a first-time biotech CEO
November 15, 2023
The rise of women’s health
October 17, 2023
Muna Therapeutics: hopeful solutions for memory loss
October 11, 2023
V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline
September 27, 2023
Lean years for company creation in Europe?
September 20, 2023
V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines
September 7, 2023
V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases
August 23, 2023
Fermenting a more sustainable future
June 21, 2023
The obesity revolution: will new drugs bring about big changes?
May 24, 2023
Fake it till you fund it?
May 15, 2023
V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
April 25, 2023
Corteria: a new strategy and approach to treating heart failure
March 29, 2023
Are we at the end of the biotech boom cycle?
March 22, 2023
The hype cycle in life sciences investments: go with the flow or fight the current?
March 2, 2023
V-Bio Ventures portfolio company Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
January 25, 2023
Coave Therapeutics: redecorating viral vectors for improved gene therapies
December 22, 2022
Why diversity matters in management teams, and how to achieve it
November 23, 2022
Cancer vaccines: not only treating tumors, but preventing them too
October 19, 2022
We need more food and agtech start-ups – and we need them now!
October 4, 2022
V-Bio Ventures leads Sibylla Biotech’s EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases
September 7, 2022
VC opportunities for impact in the face of climate disaster
August 25, 2022
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform
August 22, 2022
V-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain
August 17, 2022
Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease
June 14, 2022
Is the dot-com bubble bursting all over again?
May 12, 2022
Dualyx: restoring the body’s balance in autoimmune diseases
April 20, 2022
Drug development trends: from common to orphan indications… and back again?
March 31, 2022
V-Bio Ventures raises EUR 110 million for its second fund and expands team
March 16, 2022
Antimicrobial Resistance – the hidden killer we’re ignoring
March 16, 2022
V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals
March 1, 2022
V-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio
February 16, 2022
When should a biotech hire a CFO?
January 27, 2022
V-Bio Ventures raises additional capital to support young biotech companies
January 26, 2022
Economic Success: infinite growth is only possible in a diverse ecosystem
December 15, 2021
Long COVID: what it means for the life sciences industry and other chronic conditions
December 9, 2021
V-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals
November 24, 2021
Confo-dently into the future!
October 20, 2021
New GMOs on the horizon: say ‘cheese’!
September 21, 2021
Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?
August 18, 2021
Cancer diagnosis and therapy in one: Precirix tackles tumors with camelid antibodies
June 23, 2021
Friend or foe: building a healthy relationship with your board
June 23, 2021
Moderna: from secretive platform company to vaccine superstar
April 28, 2021
To fund or not to fund: the psychology of investment decisions
April 8, 2021
V-Bio Ventures invests in new start-up Protealis to uplift sustainable plant protein production
March 21, 2021
AgomAb’s journey of growth in regenerative medicine
February 24, 2021
V-Bio Ventures: a fresh fund with a difference
February 4, 2021
V-Bio Ventures launches its second fund at EUR 78 million
January 27, 2021
How to build the right team for start-up success
December 16, 2020
Decades-old discoveries cause paradigm shifts in modern medicine
November 4, 2020
An insightful solution to eye injections
October 27, 2020
V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals
September 30, 2020
Can Darwin’s theory explain why we get sick?
August 31, 2020
Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures
August 31, 2020
A novel approach to neurology could bring relief to people in pain
August 31, 2020
Drug combos: how much is 1 + 1?
July 28, 2020
V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19
July 7, 2020
The opioid epidemic: solutions to a painful problem
June 8, 2020
How changing diets gave rise to the world’s deadliest diseases
May 5, 2020
Cell therapies: opportunities and challenges
March 26, 2020
Potential impact of the corona crisis on the life sciences industry
February 26, 2020
Augustine Therapeutics: bridging the valley of death with VIB Discovery Sciences
January 20, 2020
V-Bio Ventures invests in RootWave in a EUR 6.5 M Series A financing to develop and market electrical weed killing solutions
January 20, 2020
Why Are Start-Ups Such Hotbeds For Innovation?
December 17, 2019
How business models shaped our current drug development trends
December 16, 2019
V-Bio Ventures invests in Augustine Therapeutics, a VIB and KU Leuven spin-off to fight neuromuscular diseases
November 26, 2019
Magic mushrooms in modern medicine
October 24, 2019
Mining the microbiome for sustainable agriculture solutions
September 24, 2019
Closing the gender gap in biotech funding: a follow-up study
August 26, 2019
The million-dollar question: How much do you charge for a lifesaving drug?
July 18, 2019
How do we reduce the high cost of clinical trials?
June 27, 2019
Betting big on blood screens for early cancer detection
May 29, 2019
OCTIMET Oncology tackling cancer with a new captain at the helm
April 16, 2019
Cultured meat, plant-based patties and bug burgers: VCs are backing protein alternatives
March 19, 2019
Closing the gender gap in biotech funding
February 19, 2019
Life after a PhD: alternatives to academia
January 22, 2019
Are we spending too much money on cancer drugs?
November 18, 2018
Why start-ups can become mega companies in the pharma sector
November 15, 2018
V-Bio Ventures leads Camel-IDS EUR 37m Series A financing
October 30, 2018
Are tech investments under threat by anti-science sentiments?
October 2, 2018
Bringing clinical trials into the home
September 18, 2018
V-Bio Ventures participates in 22.5 million euros series B financing round of Horama
August 28, 2018
Forever young: the science of aging well
July 23, 2018
Biotechs and subsidies – a fraught relationship
May 14, 2018
Acquisitions of Biotech companies: a good or a bad thing?
April 19, 2018
How to build a “European Amgen”
March 18, 2018
Is innovation killing the pharmaceutical industry?
January 18, 2018
Artificial intelligence beyond the hype: achievements and expectations in the biotech space
December 18, 2017
New cures for hereditary diseases around the corner?
November 18, 2017
Belgium vs Germany in the Life Sciences start-up championship
October 16, 2017
How Aphea.Bio managed to gather the funds to transcend from academia to industry
September 11, 2017
The leap from academia to industry
July 17, 2017
Aphea.Bio aims at leading position in next generation agricultural biologicals
May 22, 2017
Strengthening communication in biotech companies
April 17, 2017
Curing all diseases in the next 20 years: the new hype amongst billionaires?
March 16, 2017
Investing in European biotech faced with many challenges
March 15, 2017
Grail: A billion-dollar gamble?
January 18, 2017
OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors
January 12, 2017
Mosquito Wars
December 13, 2016
Confo Therapeutics: Drugging the Undruggable
December 13, 2016
V-Bio Ventures spends big money in life sciences
December 9, 2016
Biotech through the eyes of a financial analyst
December 7, 2016
Inside a life sciences fund: V-Bio Ventures
December 1, 2016
V-Bio Ventures announces the final closing of its first fund, raises over €75 million